Fig. 5.

HSP90 inhibitor 17-DMAG suppresses the growth of Cal27 xenografts in vivo. (A) Representative images of Cal27 xenografts in each group of mice after 20 days (8 sites in 4 mice). Mice received i.p. injection of 10 mg/kg 17-DMAG, or equivalent DMSO in PBS 5 days per week, respectively. (B) Tumor volumes changing of Cal27 xenograft in DMSO, or 17-DMAG treated mice. Tumor volumes were calculated with length×width²/2 of the xenograft (*p<0.05, **p<0.01). (C) Weights of the xenografts were compared between DMSO and 17-DMAG treated mice (*p<0.05). (D) H&E staining and immunohistochemistry staining of CHIP and CD166 in consecutive sections of Cal27 xenografts in DMSO and 17-DMAG treated mice; bar=100 µm. (E) Schematic model for the degradation of CD166 through the ubiquitin-proteasome pathway mediated by CHIP.